#1 Respiratory Care Solution
OtherRespiratory care solution.
NCT Number: NCT01688440
When babies are sick, or are born prematurely, they sometimes need an endotracheal (ET) tube to assist their breathing and/or a nasal canula. The investigators must periodically irrigate the ET tube to prevent them from being plugged up by secretions. The investigators also, due to the drying effects of nasal canula, periodically moisten the nasal passages of babies. Presently 0.9% saline is the solution being used for moistening of the ET tube, nose, as well as oral cares will infant is not eating. However, scientists have recently learned that saline can destroy the body's natural antibacterial properties in the windpipe, nose, and mouth.
The investigators have developed a new solution to be used in place of saline for endotracheal (ET), nasal, and oral cares. The investigators' new solution is patterned after the natural fluid in the windpipe, nose, and mouth.
Study Hypothesis:
1. Patients who receive ETCare will have no increase in adverse events related to its administration, compared with 0.9% saline. 2. Patients who receive ETCare will have a lower proportion of tracheal aspirates where pathogens are reported. 3. Patients who receive ETCare will have a lower proportion of tracheal aspirates where leukocytes are reported. 4. Patients who receive ETCare will have fewer (risk-adjusted) days of supplemental oxygen.
Looking for future studies?
Notify MeAll sexes
Interventional
Early Phase 1
McKay-Dee Hospital Center, Ogden, Utah, United States
Normal saline (0.9% sodium chloride) is used by virtually all neonatal intensive care units to periodically irrigate the endotracheal tube of neonates who require mechanical ventilation. This practice is intended to reduce the risk that thick secretions will occlude the endotracheal tube. Normal saline is also occasionally used to periodically clear the nasal passages of neonates on nasal CPAP or nasal canula oxygen. It is also occasionally used as a means of periodically moistening the mouth of neonates who have an endotracheal tube in place, because the tube prevents lip apposition and results in a dry mouth.
The problem with the current method of using normal saline for periodic endotracheal, nasal, and/or oral care is that high concentrations of sodium and chloride have recently been found to rapidly and completely inactivate the natural antimicrobial properties of tracheal effluent, nasal secretions, and saliva. Tracheal secretions, nasal secretions, and saliva contain potent antibacterial substances. One such that was recently described is a 37 amino acid peptide with widespread antimicrobial properties, termed "LL-37". It has recently been shown that 0.9% saline inactivates the antimicrobial properties of LL-37 and significantly damages the overall antibacterial actions of tracheal secretions, nasal secretions, and saliva. Further research has shown that the high sodium and chloride content of saliva of patients with cystic fibrosis inactivates the antimicrobial properties, thus partly explaining the high incidence of airway infections in these patients. Moreover, a family with deficient LL-37 has been described in Sweden, and these individual all have chronic gingivostomatitis and airway infections. Therefore, our current practice of instilling 0.9% sodium chloride likely inactivates the major innate anti-microbial defense system of the upper airway. Perhaps reducing immune capacity in the upper airway with this practice unwittingly contributes to the high incidence of upper airway infections among intubated neonates.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Respiratory care solution.
Time frame: To discharge home (about one month).
Renal hematological and hepatic function.
Time frame: Day of administration (one day)
Desaturation, bradycardia, tachydardia, hypotension, or hypertension or skin rashes.
Intermountain Health Care, Inc.
Other
"ETCare": A Phase II, Safety and Preliminary Efficacy Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07693530
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT00814099
Acute Lung Injury, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT05065424
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Dallas, Texas, United States
View Trial DetailsNCT07422116
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Jakarta Pusat, DKI Jakarta, Indonesia
View Trial Details